GNMX ETF Price & Analysis

The Corgi Genomics & Precision Medicine ETF (GNMX) is a sector-focused, theme-driven exchange-traded fund designed to deliver targeted exposure to the companies creating the next generation of healthcare through genomic science and precision medicine. Seeking capital appreciation, GNMX concentrates on firms whose products, platforms and services enable DNA- and data-driven diagnostics, therapies and drug discovery — from genomic sequencing and gene editing to molecular diagnostics, bioinformatics, companion diagnostics and personalized therapeutics. GNMX’s investable universe spans established pharmaceutical and medtech companies as well as small- and mid-cap biotechnology and platform specialists that provide the tools, pipelines and analytics powering genomic innovation. Typical holdings include gene-therapy developers, CRISPR and gene-editing firms, clinical-stage biotechs working on precision oncology and rare-disease treatments, sequencing and diagnostic equipment makers, and software and AI firms that translate genomic data into clinical decision support. Positioned in the Genomic Advancements niche, GNMX offers investors a concentrated way to participate in structural growth trends: falling sequencing costs, accelerating adoption of targeted therapies, expansion of precision diagnostics and the integration of genomics into routine care. The fund may hold securities across market capitalizations and geographies, including U.S. equities and global listings, to capture the full spectrum of innovation. As a thematic, growth-oriented vehicle, GNMX is suited for investors seeking exposure to disruptive biomedical technologies and long-term capital appreciation. Prospective investors should be aware that concentrated exposure to the genomics and precision medicine theme can entail higher volatility and company-specific risk relative to broad healthcare benchmarks.